drugset
Drugs / insulin degludec/liraglutide
last change Feb 2018 re-read 2 minutes ago

insulin degludec/liraglutide

also known as IDegLira
Developed for
type 2 diabetes mellitus
Investigated by
Novo Nordisk A/S

Trials 1 · a red edge is where a trial was stopped

today NCT02420262 · Ph 3
20162017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT02420262 Jul 2015 → Oct 2016 type 2 diabetes mellitus Novo Nordisk A/S Completed No outcome recorded

Press releases naming this drug 14 releases

DateIssuerRelease
2016-09-02 Novo Nordisk A/S FDA forlænger registreringsprocessen for IDegLira med tre måneder novonordisk.com ↗
2016-09-02 Novo Nordisk A/S FDA extends regulatory review period for IDegLira by three months novonordisk.com ↗
2016-05-24 Novo Nordisk A/S FDA's rådgivende komite anbefaler godkendelse af IDegLira med stemmerne 16-0 novonordisk.com ↗
2016-05-24 Novo Nordisk A/S IDegLira receives positive 16-0 vote in favour of approval from FDA Advisory Committee novonordisk.com ↗
2016-05-20 Novo Nordisk A/S FDA offentliggør briefingmateriale forud for møde i rådgivende komite om IDegLira, en kombination af insulin degludec og liraglutid novonordisk.com ↗
2016-05-20 Novo Nordisk A/S FDA posts briefing materials prior to Advisory Committee meeting for IDegLira, a fixed combination product of insulin degludec and liraglutide novonordisk.com ↗
2014-09-18 Novo Nordisk A/S Xultophy® (IDegLira) approved in Europe novonordisk.com ↗
2014-09-18 Novo Nordisk A/S Xultophy® (IDegLira) godkendt i Europa novonordisk.com ↗
2014-07-25 Novo Nordisk A/S Novo Nordisk modtager positiv udtalelse om Xultophy® (IDegLira) fra de europæiske registreringsmyndigheder novonordisk.com ↗
2014-07-25 Novo Nordisk A/S Novo Nordisk receives positive opinion on Xultophy® (IDegLira) from the European regulatory authorities novonordisk.com ↗
2013-05-31 Novo Nordisk A/S Novo Nordisk indsender registreringsansøgning for IDegLira i EU til behandling af type 2-diabetes novonordisk.com ↗
2013-05-31 Novo Nordisk A/S Novo Nordisk files for regulatory approval of IDegLira in the EU for the treatment of type 2 diabetes novonordisk.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as insulin degludec/liraglutide ClinicalTrials.gov intervention name — accepted as the source's own label NCT02420262 ↗
Known as IDegLira “insulin degludec/liraglutide fixed-ratio combination (IDegLira) versus basal-bolus insulin” PMID 29483185 ↗ Feb 2018
Route Subcutaneous “Once daily injected s.c./subcutaneously (under the skin)” NCT02420262 ↗